Vesicular monoamine transporters (VMATs) are essential for proper monoaminergic neurotransmission, which requires the sequestration of the transmitter into synaptic vesicles by VMAT for subsequent Ca²⁺-stimulated exocytotic release. VMATs contain 12 transmembrane spanning domains, with cytosolic C- and N-terminals and large glycosylated intravesicular loops. In mammals, there are two VMAT isoforms: VMAT1 (SLC18A1) and VMAT2 (SLC18A2)¹.

VMATs primarily transport monoamines (dopamine, serotonin, norepinephrine and histamine), but also sequester toxicants into vesicles, shunting them away from cytosolic sites of action. In the central nervous system, VMAT2 is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release².

VMAT2 is expressed in monoaminergic neurons of the central nervous system (CNS) and sympathetic postganglionic neurons. VMAT2 is widely expressed during embryonic development³.

Homozygous knock-out of VMAT2 in mice is lethal and heterozygous knock-out of VMAT2 in mice shows a clear gene dosage effect, with half the amount of dopamine, norepinephrine, and serotonin content in brain⁴. In addition VMAT2 plays a role in neuroprotection and molecules that interact with VMAT2 may have value as treatments for diseases such as Parkinson’s disease⁵.